A phycocyanin derived eicosapeptide attenuates lung fibrosis development.

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Pulmonary fibrosis (PF) is a progressive respiratory disease characterized by inflammation and tissue destruction.
• Epithelial-mesenchymal transition (EMT) plays a crucial role in the pathogenesis of PF.
• Novel therapeutic strategies targeting fibrotic pathways are urgently needed.

Purpose of the Study:

• To investigate the anti-fibrotic effects of phycocyanin derived eicosapeptide (PP20).
• To elucidate the underlying molecular mechanisms of PP20's action, focusing on TGF-β/Smad and MAPK signaling pathways.
• To evaluate PP20's potential as a therapeutic agent for pulmonary fibrosis.

Main Methods:

• Induction of pulmonary fibrosis in mice using oleic acid (OA).
• Exposure of A549 and HFL-1 cells to TGF-β1 with or without PP20 treatment.
• Analysis of fibrotic markers, EMT, and TGF-β/Smad and MAPK signaling pathways using agonists and animal/cell models.

Main Results:

• PP20 significantly reduced inflammation, tissue damage, and collagen deposition in OA-induced mice.
• PP20 inhibited TGF-β1-induced EMT, collagen I, and α-SMA expression in A549 and HFL-1 cells.
• PP20 demonstrated negative regulation of TGF-β/Smad and MAPK pathways, confirming its anti-fibrotic properties.

Conclusions:

• PP20 exhibits potent anti-fibrotic activity by mitigating inflammation and inhibiting EMT.
• PP20's mechanism involves the negative regulation of TGF-β/Smad and MAPK signaling pathways.
• PP20 represents a promising therapeutic candidate for the treatment of pulmonary fibrosis.